ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ACR"

  • Abstract Number: 650 • 2019 ACR/ARP Annual Meeting

    Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients

    Eunyoung Lee1, Eun Bong Lee 2, Eun Young Lee 1, Jin Kyun Park 3, Se Han Ahn 4 and Yeong-Wook Song 5, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Seoul-t'ukpyolsi, Republic of Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Gwacheon-si, Kyonggi-do, Republic of Korea, 5Seoul National University Hospital, Seoul, Republic of Korea

    Background/Purpose: To evaluate the performance of the proposed American College of Rheumatology/European League against Rheumatism (ACR/EULAR) classification criteria for systemic lupus erythematosus (SLE) in Korean…
  • Abstract Number: 1348 • 2019 ACR/ARP Annual Meeting

    Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials

    Louis Bessette1, Maxime Dougados 2, Eduardo Mysler 3, Mark Genovese 4, Cassandra Kinch 5, Kenneth Kwok 6, Tatjana Lukic 6, Tanya Girard 5, Pierre-Alexandre Landry 5 and Ronald van Vollenhoven 7, 1Laval University, Quebec City, QC, Canada, 2Cochin Hospital, Paris, France, 3Organización Médica de Investigación, Buenos Aires, Argentina, 4Stanford University, Stanford, CA, 5Pfizer Canada ULC, Kirkland, QC, Canada, 6Pfizer Inc, New York, NY, 7Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. In clinical trials, standard criteria for measuring treatment efficacy in patients (pts) with…
  • Abstract Number: 1484 • 2019 ACR/ARP Annual Meeting

    The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis

    Peter Nash1, Maria Greenwald 2, Liang-Hung Lin 3, Wei Yu 4, Paul Santos Estrella 5, Rajiv Mundayat 6, Daniela Graham 7 and Douglas Veale 8, 1University of Queensland, Brisbane, Queensland, Australia, 2Desert Medical Advances, Palm Desert, CA, 3AIR, Taichung Tzu Chi Hospital, Taichung City, Taiwan (Republic of China), 4Pfizer Inc, Beijing, China (People's Republic), 5Pfizer Inc, Makati, Philippines, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Groton, CT, 8EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland

    Background/Purpose: Early identification, diagnosis, and treatment of psoriatic arthritis (PsA) is important in preventing long-term joint damage and disability, and the associated socioeconomic consequences.1 Tofacitinib…
  • Abstract Number: 1254 • 2018 ACR/ARHP Annual Meeting

    QI Project: Inpatient Practices in Ordering Fluorescent Anti-Nuclear Antibodies (F-ANA) and ANA Subserologies in a City Hospital in an Underserved Community

    Ivan Emil Ramirez de Oleo1, Beverly Johnson2,3 and Barbara Mendez-Agrusa4, 1Internal Medicine, Jacobi Medical Center, Bronx, NY, 2Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, 3Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 4Medicine, Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: It is important for internists to know how to appropriately and effectively order subspecialty labs. As part of the choosing wisely campaign in 2013,…
  • Abstract Number: 1681 • 2018 ACR/ARHP Annual Meeting

    Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases

    Chengappa KG1, Gunjan Kumar2, Swaminathan R P3 and Vir Singh Negi1, 1Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, 2Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India, 3Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India

    Background/Purpose: A new classification criteria for SLE was proposed at the ACR/ARHP 2017 annual meet. The aim of this study was to compare the performance…
  • Abstract Number: 2578 • 2018 ACR/ARHP Annual Meeting

    Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients

    C. Steven Ernest II, Nieves Velez de Mendizabal and Leijun Hu, Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A. It has been approved to treat adult patients with moderate-to-severe plaque psoriasis and…
  • Abstract Number: 588 • 2018 ACR/ARHP Annual Meeting

    Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis

    Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy

    Background/Purpose: The ACR Hybrid, officially recommended by the ACR as a revision to the ACR20/50/70 response criteria, combines the ACR20/50/70 scores with the mean percent…
  • Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting

    Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic

    Aparna Das, Rajarajan Panneerselvan, Annum Faisal, Jubran Rind and Rima Shah, Internal medicine, Michigan state university, grand rapids, MI

    Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…
  • Abstract Number: 17L • 2017 ACR/ARHP Annual Meeting

    Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study

    Philip J Mease1, Désirée van der Heijde2, Robert B.M. Landewé3, Shephard Mpofu4, Proton Rahman5, Hasan Tahir6, Atul Singhal7, Elke Böttcher8, Sandra V. Navarra9, Karin Meiser4, Aimee Readie10, Luminita Pricop10 and Ken Abrams10, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Leiden University Medical Center, Leiden, Netherlands, 3Academic Medical Center, Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 4Novartis Pharma AG, Basel, Switzerland, 5Rheumatology, Memorial University of Newfoundland, St Johns, NF, Canada, 6Whipps Cross Hospital, London, United Kingdom, 7Southwest Rheumatology, Dallas, TX, 8Rheumazentrum Favoriten, Vienna, Austria, 9Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has shown significant and rapid efficacy in psoriatic arthritis (PsA). We present primary results…
  • Abstract Number: 105 • 2017 ACR/ARHP Annual Meeting

    Tweeting the Meeting: Analysis of Twitter Use during the American College of Rheumatology 2016 Annual Meeting

    Mosaab Mohameden1, Victoria Malkhasyan2, Baker Alkhairi3, Najla Aljaberi4 and Candice Yuvienco5, 1Internal Medicine, University of California San Francisco - Fresno Medical Education Program, Fresno, CA, 2University of California San Francisco - Fresno Medical Education Program, Fresno, CA, 3Internal Medicine, Blake Medical Center, Bradenton, FL, 4Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 5Internal Medicine, Division of Rheumatology Director, University of California San Francisco, Fresno Medical Education Program, Fresno, CA

    Background/Purpose: The American College of Rheumatology (ACR) annual meeting is the premier rheumatology research and education event of the year. The ACR adopted the use…
  • Abstract Number: 356 • 2017 ACR/ARHP Annual Meeting

    Preliminary Real World Data on Switching Patterns between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry

    Rieke Alten1, Petra Neregard2, Heather Jones3, Ena Singh4, Cinzia Curiale5, Thomas Meng6, Lara Lucchese7, Cristiana Miglio7 and Gudrun Jonasdottir Bergman8, 1Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 2Pfizer, Stochholm, Sweden, 3Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, 4Pfizer, Collegeville, PA, 5Pfizer, Rome, Italy, 6Pfizer, Berlin, Germany, 7QuintilesIMS, London, United Kingdom, 8QuintilesIMS, Solna, Sweden

    Background/Purpose: The increasing availability of biologic treatments over the past 10 years has revolutionized the management of rheumatic diseases. In April 2016, the first etanercept…
  • Abstract Number: 505 • 2017 ACR/ARHP Annual Meeting

    Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy

    Ben Klünder1, Mohamed-Eslam F. Mohamed2, Heidi S. Camp2 and Ahmed A. Othman2, 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 2AbbVie, North Chicago, IL

    Background/Purpose: Upadacitinib, a selective JAK1 inhibitor, demonstrated favorable efficacy in two Phase 2 studies in subjects with moderate to severe rheumatoid arthritis (RA) who had…
  • Abstract Number: 618 • 2017 ACR/ARHP Annual Meeting

    Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial

    Paul Emery1, Iain B. McInnes2, Philip J Mease3, Michael Schiff4, Luminita Pricop5, Steven Shen5, Zailong Wang5 and Corine Gaillez6, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Swedish Medical Center and University of Washington, Seattle, WA, 4University of Colorado, Denver, CO, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…
  • Abstract Number: 624 • 2017 ACR/ARHP Annual Meeting

    Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial

    Philip S. Helliwell1, Eric Lespessailles2, Catherine Shuler3, Lotus Mallbris3, Janelle Erickson3 and Roy Fleischmann4, 1St. Luke's Hospital and University of Leeds, Bradford, United Kingdom, 2University Orleans, Orleans, France, 3Eli Lilly and Company, Indianapolis, IN, 4Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. In the SPIRIT-P1 phase 3 study (NCT01695239), IXE was superior to placebo…
  • Abstract Number: 734 • 2017 ACR/ARHP Annual Meeting

    Correlation of the American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis with Serum Biomarkers of Fibrogenesis in an Observational Cohort

    Giuseppina Abignano1, Sookhoe Eng2, Maya H. Buch3, Paul Emery4, Dinesh Khanna5 and Francesco Del Galdo2, 1Rheumatology Department of Lucania,, Rheumatology Institute of Lucania (IReL), San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera,, Potenza, Italy, 2Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5University of Michigan, Ann Arbor, MI

    Background/Purpose: The CRISS is a composite index of response in diffuse cutaneous systemic sclerosis (dcSSC). It is a 2-step process for the probability of improvement…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology